Tnpx or repl , which one i should buy ?

The decision between **Tonix Pharmaceuticals (TNXP)** and **Replimune Group (REPL)** depends on your risk tolerance, investment horizon, and the weight you give to potential short-term vs. long-term gains. Here's a breakdown to help you make an informed choice:

1. **Tonix Pharmaceuticals (TNXP)**:
- **Technical Strength**: TNXP is currently in a strong uptrend, closing above key moving averages and forming a symmetrical triangle pattern, which suggests a high probability of breakout.
- **Regulatory Catalyst**: The FDA decision for TNX-102 SL in fibromyalgia is scheduled for August 15, 2025, which could significantly impact the stock price.
- **Analyst Confidence**: Analysts have set an average target price of $61.67, reflecting a substantial upside from the current price.
- **Strategic Pipeline**: TNX-1500 for organ transplant rejection and TNX-4200 for broad-spectrum antiviral are long-term growth drivers.
- **Risk Factors**: The recent shelf filing could indicate increased volatility and potential dilution.

|code|Ticker|Name|Date|Support Level|Resistance Level|market_code|
|---|---|---|---|---|---|---|
|TNXP|TNXP.O|Tonix|20250701|32.3600|36.9700|186|

|code|Ticker|Name|Date|Moving Average|market_code|
|---|---|---|---|---|---|
|TNXP|TNXP.O|Tonix|20250701|35.5400|186|

2. **Replimune Group (REPL)**:
- **Regulatory Milestone**: REPL is awaiting an FDA decision for RP1 in advanced melanoma, with a PDUFA date set for July 22, 2025, which could be a catalyst for the stock.
- **Commercial Readiness**: REPL's manufacturing facility is prepared for commercial launch, indicating potential for rapid scaling.
- **Analyst Sentiment**: Cantor Fitzgerald initiated REPL with an "Overweight" rating, indicating positive expectations.
- **Financial Position**: REPL has a strong cash position, expected to fund operations into Q4 2026.
- **Risk Factors**: Net losses have been substantial, and the IGNYTE-3 trial could introduce delays in further validating RP1.

|code|Ticker|Name|Date|Closing Price|Percentage Change|Trading Volume|market_code|
|---|---|---|---|---|---|---|---|
|REPL|REPL.O|Replimune Group|20250701|9.15|-1.5069967707211926|1675547|185|

|code|Ticker|Name|Date|Support Level|Resistance Level|market_code|
|---|---|---|---|---|---|---|
|REPL|REPL.O|Replimune Group|20250701|9.0800|9.8300|185|

|code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code|
|---|---|---|---|---|---|---|---|---|
|REPL|REPL.O|Replimune Group|20250701|9.6480|33.7748|25.5175|-0.1851|185|

**Conclusion**: If you prioritize **near-term potential** and are comfortable with **higher risk**, TNXP might be the better choice, given the upcoming FDA decision and analyst targets. If you prefer **long-term growth potential** and are looking for a **more stable entry point**, REPL could be the better fit, especially with its upcoming FDA decision and strong analyst sentiment.

Consider your investment goals, risk tolerance, and the timing of the potential FDA decisions when making your decision. It's also advisable to review the latest company news and SEC filings to stay informed about any developments that might impact your investment thesis.